Theranos was touted as a high-flying disruptor in the $75 billion U.S. blood testing market dominated by incumbents like Abbott, Quest Diagnostics, LabCorp, Roche, Thermo-Fisher, Becton Dickinson and other big…
Stay informed with Paul’s unique perspective on healthcare happenings, from policies and politics to innovations and investments. Subscribe today to the Keckley Report and be the first to receive Paul’s weekly insights and special reports.